36 research outputs found
Forskolin-induced Organoid Swelling is Associated with Long-term CF Disease Progression
RATIONALE: Cystic fibrosis (CF) is a monogenic life-shortening disease associated with highly variable individual disease progression which is difficult to predict. Here we assessed the association of forskolin-induced swelling (FIS) of patient-derived organoids (PDO) with long-term CF disease progression in multiple organs and compared FIS with the golden standard biomarker sweat chloride concentration (SCC). METHODS: We retrieved 9-year longitudinal clinical data from the Dutch CF Registry of 173 people with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Individual CFTR function was defined by FIS, measured as the relative size increase of intestinal organoids after stimulation with 0.8â
”M forskolin, quantified as area under the curve (AUC). We used linear mixed effect models and multivariable logistic regression to estimate the association of FIS with long-term FEV1pp decline and development of pancreatic insufficiency, CF-related liver disease and diabetes. Within these models, FIS was compared with SCC. RESULTS: FIS was strongly associated with longitudinal changes of lung function, with an estimated difference in annual FEV1pp decline of 0.32% (95%CI: 0.11%-0.54%; p=0.004) per 1000-points change in AUC. Moreover, increasing FIS levels were associated with lower odds of developing pancreatic insufficiency (adjusted OR: 0.18, 95%CI: 0.07-0.46, p<0.001), CF-related liver disease (adjusted OR: 0.18, 95%CI: 0.06-0.54, p=0.002) and diabetes (adjusted OR: 0.34, 95%CI: 0.12-0.97, p=0.044). These associations were absent for SCC. CONCLUSION: This study exemplifies the prognostic value of a PDO-based biomarker within a clinical setting, which is especially important for people carrying rare CFTR mutations with unclear clinical consequences
Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
Cystic fibrosis (CF) is an inherited disorder where individual disease etiology and response to therapeutic intervention is impacted by CF transmembrane regulator (CFTR) mutations and other genetic modifiers. CFTR regulates multiple mechanisms in a diverse range of epithelial tissues. In this Review, we consolidate the latest updates in the development of primary epithelial cellular model systems relevant for CF. We discuss conventional two-dimensional (2-D) airway epithelial cell cultures, the backbone of in vitro cellular models to date, as well as improved expansion protocols to overcome finite supply of the cellular source. We highlight a range of strategies for establishment of three dimensional (3-D) airway and intestinal organoid models and evaluate the limitations and potential improvements in each system, focusing on their application in CF. The in vitro CFTR functional assays in patient-derived organoids allow for preclinical pharmacotherapy screening to identify responsive patients. It is likely that organoids will be an invaluable preclinical tool to unravel disease mechanisms, design novel treatments, and enable clinicians to provide personalized management for patients with CF
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
Background
Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF).
Methods
We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection.
Results
Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133).
Conclusions
SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination
Application of human organoids in ion transport studies
Organoid cultures won the âmethod of the yearâ award from Nature Methods in 2018. These primary human stem cell-based cultures were used to develop disease models and drug development assays. Furthermore, the 3D cultures consist of individual-specific epithelial cells and can be passaged on the long-term. Our aims were to validate the intestinal organoid model for cystic fibrosis, and to develop new applications of this model to study epithelial ion transport of CFTR. To achieve these goals, we used intestinal organoids from healthy subjects and subjects with CF to determine CFTR function (residual function and modulated function upon drug treatment) via organoid swelling. We showed that 3D intestinal organoids from subjects with CF can be used to determine efficacy of drugs that repair premature termination codons. Via a drug screening with organoids, we found that B2-adrenergic receptor agonists could enhance CFTR activity in intestinal organoids as well as subjects with CF. We generated 2D monolayers from intestinal organoids of various subjects with CF, and developed a electrophysiological assay to study ion transport in these cultures. The CFTR-dependent ion transport measurements correlated well with outcomes of donor-matched rectal biopsies and intestinal organoids. We developed a protocol to generate and culture airway organoids on the long-term, and showed that we could model CF and other diseases. To generate airway organoids, lung biopsies are needed or cells from a broncho-alveolar lavage. For CF, we could measure and discriminate CFTR activity as well as activity of the so-called alternative ion channel TMEM16A. With both intestinal and airway organoids, we showed how to identify side effects of ion transport modulators. We also used the intestinal organoid model for determining the potency of cholera toxin inhibitors. Stem cell technologies are valuable tools to develop new culture models for better modeling of disease and drug development. These models are patient-specific and can be cultured on the long-term. We showed that ion transport capacities in intestinal and airway organoids recapitulate essential characteristics of CF and drug response. Additional applications are needed to further utilize the opportunities of these technologies
Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons
Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
Background
Although short-term efficacy of lumacaftor/ivacaftor and tezacaftor/ivacaftor is clearly established in clinical trials, data on long-term effectiveness is limited. This registry-based cohort study assessed real-world longitudinal outcomes of F508del-homozygous people with cystic fibrosis (pwCF) â„12â
years, up to 3â
years after the introduction of dual cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Methods
Annual data (2010â2019) were retrieved from the Dutch Cystic Fibrosis Registry. Longitudinal trends of per cent predicted forced expiratory volume in 1â
s (FEV1 % pred) decline, body mass index (BMI), BMI Z-score and intravenous antibiotic treatment duration before and after CFTR modulator initiation were assessed with linear and negative binomial mixed models.
Results
We included 401 participants (41.9% female, baseline age 24.5â
years (IQR 18.0â31.5â
years), baseline mean±sd FEV1 70.5±23.4% pred). FEV1 decline improved from â1.36% pred per year to â0.48% pred per year after modulator initiation (change: 0.88% pred, 95% CI: 0.35â1.39%, p=0.001). This change was even 1.40% pred per year (95% CI: â0.0001â2.82%, p=0.050) higher in participants with baseline FEV1 <40% pred. In adults, annual BMI trend was not altered (change: 0.10â
kg·mâ2·yearâ1, 95% CI:â0.01â0.21, p=0.079). Annual BMI Z-score in children reversed from â0.08 per year before modulator treatment to 0.06 per year afterwards (change: 0.14 per year, 95% CI: 0.06â0.22, p<0.001). Intravenous antibiotic treatment duration showed a three-fold reduction in the first year after modulator initiation (incidence rate ratios (IRR): 0.28, 95% CI: 0.19â0.40, p<0.001), but the annual trend did not change in the subsequent years (IRR: 1.19, 95% CI: 0.94â1.50, p=0.153).
Conclusion
Long-term effectiveness of dual CFTR modulator therapies on FEV1 decline, BMI and intravenous antibiotic treatment duration is less pronounced in a real-world setting than in clinical trials and varies considerably between pwCF and different baseline FEV1 levels
Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity
Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic FibrosisResearch in context
Summary: Background: Generic and disease-specific patient-reported outcome measures (PROMs) may lack relevance and sensitivity on a patient-level in chronic diseases with differential disease expression and high individual variability, such as Cystic Fibrosis (CF). This study aimed to develop and validate a novel personalized electronic PROM (ePROM) that captures relevant aspects of quality of life in individuals with CF. Methods: The Q-Life app was developed as a short personalized ePROM to assess individual quality of life. Psychometric properties were assessed in a single-center cross-sectional study between September 2019 and September 2021 and in a prospective cohort study between September 2021 and September 2022. Findings: Combined studies included 223 participants (median age: 24 years, IQR: 19.0â32.5 years, range: 12.0â58.0 years). Internal consistency (Cronbach's alpha: 0.83â0.90) and test-retest reliability (intraclass correlation coefficient: 0.90; 95% CI: 0.65â0.92; p < 0.001) of quality of life (Q-Life) scores were strong. Q-Life scores were associated with overall Cystic Fibrosis Questionnaire-Revised (CFQ-R) scores (Ï = 0.71; p < 0.001), CFQ-R respiratory domain scores (Ï = 0.57; p < 0.001) and forced expiratory volume in 1s (Ï = 0.41; p < 0.001). Furthermore, Q-Life scores improved from 65.0 (IQR: 45.0â63.3) at baseline to 84.2 (IQR: 75.0â95.0) and 87.5 (IQR: 75.0â100.0) after 3 and 6 months of elexacaftor/tezacaftor/ivacaftor treatment (change: 20.8; 95% CI: 17.5â25.0; p < 0.001), comparable to CFQ-R respiratory domain scores (change: 22.2, 95% CI: 19.4â25.0, p < 0.001). Interpretation: The Q-Life app is a reliable, valid and sensitive personalized ePROM to measure all aspects of quality of life that really matter to individuals with Cystic Fibrosis. This patient-centered approach could provide important advantages over generic and disease-specific PROMs in the era of personalized medicine and value-based healthcare. Funding: Dutch Cystic Fibrosis Foundation, Health-Holland
Functional characterization of cholera toxin inhibitors using human intestinal organoids
Preclinical drug testing in primary human cell models that recapitulate disease can significantly reduce animal experimentation and time-to-the-clinic. We used intestinal organoids to quantitatively study the potency of multivalent cholera toxin inhibitors. The method enabled the determination of IC50 values over a wide range of potencies (15 pM to 9 mM). The results indicate for the first time that an organoid-based swelling assay is a useful preclinical method to evaluate inhibitor potencies of drugs that target pathogen-derived toxins